Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
Open Access
- 1 January 2013
- journal article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 28 (2), 165-173
- https://doi.org/10.3904/kjim.2013.28.2.165
Abstract
Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. We prospectively enrolled 55 consecutive patients with ACS: 25 with unstable angina (UA) and 30 with non-ST elevated myocardial infarction (NSTEMI). For comparison, 25 age- and sex-matched subjects with no significant coronary artery stenosis were included as the control group. Peripheral serum levels of interleukin (IL)-33, matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and C-reactive protein (CRP) were measured on admission, and at 12, 24, 48, and 72 hours after the initial evaluation. Compared to serum levels in the control group, serum levels of IL-33 decreased in the NSTEMI group (p < 0.05), and levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 increased in the UA group (p < 0.01, p < 0.05, respectively) and NSTEMI group (p < 0.05, p < 0.05, respectively). IL-33 levels were significantly lower on admission than at 12 hours after the initial evaluation (p < 0.05). IL-33 levels were negatively correlated with MMP-9 levels (r = -0.461, p < 0.05) and CRP levels (r = -0.441, p < 0.05). Elevated levels of MMP-9, TIMP-1, and decreased levels of IL-33 play a role in the development and progression of ACS.Keywords
This publication has 41 references indexed in Scilit:
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- IL-33 Reduces Macrophage Foam Cell FormationPublished by The American Association of Immunologists ,2010
- Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic LoadJournal of the American College of Cardiology, 2008
- Nuclear Interleukin-33 Is Generally Expressed in Resting Endothelium but Rapidly Lost upon Angiogenic or Proinflammatory ActivationThe American Journal of Pathology, 2008
- Clinical Implications of Elevated Serum Interleukin‐6, Soluble CD40 Ligand, Metalloproteinase‐9, and Tissue Inhibitor of Metalloproteinase‐1 in Patients with Acute ST‐segment Elevation Myocardial InfarctionClinical Cardiology, 2008
- IL-33 reduces the development of atherosclerosisThe Journal of Experimental Medicine, 2008
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJCI Insight, 2007
- Increased Pericardial Fluid Level of Matrix Metalloproteinase-9 Activity in Patients With Acute Myocardial Infarction Possible Role in the Development of Cardiac RuptureCirculation Journal, 2006
- MMPs - Role in Cardiovascular Development and DiseaseFrontiers in Bioscience-Landmark, 2006
- Elevation of Plasma Matrix Metalloproteinase-9 in the Culprit Coronary Artery in Patients With Acute Myocardial Infarction Clinical Evidence From Distal ProtectionCirculation Journal, 2005